SCHEMBL12371694

SCHEMBL12371694

O=c1[nH]c2cnc(NCC3CCCNC3)nc2n1Cc1c(F)cccc1C(F)(F)F

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 1/20 0.41
ADORA1 P30542 1/20 0.41
CHEK1 O14757 7/20 0.41
JAK2 O60674 2/20 0.39
JAK3 P52333 2/20 0.39
PTPN11 Q06124 1/20 0.38
MAP4K1 Q92918 1/20 0.38
FLT3 P36888 2/20 0.37
CCNT1 O60563 2/20 0.36
CCNK O75909 1/20 0.36
CCNE1 P24864 1/20 0.36
CDK2 P24941 1/20 0.36
CDK9 P50750 1/20 0.36
CDK12 Q9NYV4 1/20 0.36
USP1 O94782 4/20 0.36
BRD4 O60885 1/20 0.35
ATAD2 Q6PL18 1/20 0.35
IRAK4 Q9NWZ3 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12371644 0.95 ADORA2A (0.42) ADORA2AADORA1CHEK1JAK2JAK3
SCHEMBL12371634 0.95 ADORA2A (0.42) ADORA2AADORA1CHEK1JAK2JAK3
SCHEMBL12371683 0.88 CHEK1 (0.42) ADORA2ACHEK1PTPN11FLT3CCNT1
SCHEMBL12371680 0.88 CHEK1 (0.42) ADORA2ACHEK1PTPN11FLT3CCNT1
SCHEMBL12371653 0.88 ADORA2A (0.47) ADORA2AADORA1JAK2JAK3USP1
SCHEMBL12371677 0.84 JAK2 (0.44) CHEK1JAK2JAK3CCNT1CDK9
SCHEMBL12371674 0.84 JAK2 (0.44) CHEK1JAK2JAK3CCNT1CDK9
SCHEMBL12371638 0.84 ADORA2A (0.45) ADORA2AADORA1JAK2JAK3CCNT1
SCHEMBL13608275 0.84 ADORA2A (0.45) ADORA2AADORA1JAK2JAK3CCNT1
SCHEMBL12371650 0.83 CHEK1 (0.41) ADORA2ACHEK1PTPN11MAP4K1FLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989459-B2 Protein kinase C (PKC); rheumatoid arthritis, lupus, transplant rejection, asthma, inflammatory bowel disease, cancer and diabetes; for example, 2-(pyrrolidin-3-ylmethylamino)-9-(2-trifluoromethoxybenzyl)-7,8-dihydro-9H-purin-8-one PHARMACOPEIA, LLC (US) 2011-08-02 US disclosed
WO-2008143674-A1 PURINONES AND 1H-IMIDAZOPYRIDINONES AS PKC-THETA INHIBITORS PHARMACOPEIA, INC. (US) 2008-11-27 WO disclosed
US-20080085909-A1 Purinones and 1H-imidazopyridinones as PKC-theta inhibitors PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2008-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085909-A1 Purinones and 1H-imidazopyridinones as PKC-theta inhibitors PRKCE, PRKCH, PRKCQ ADORA2A 995/4885ADORA1 1307/4885CHEK1 520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.